Immune checkpoint molecules such as programmed death-1 (PD-1) and its ligand (PD-L1) are negative regulators of T-cell-mediated antitumor response. PD-L1 is aberrantly expressed in several malignancies, including clear cell renal cell carcinoma (ccRCC), and this may be associated with an unfavorable prognosis and adverse clinico-pathologic features. 
INTRODUCTION
Kidney cancer accounts for at least 3% of malignant diseases (1) . The incidence and mortality of renal cell carcinoma (RCC) seem to be rising, and approximately 65,000 new cases are diagnosed every year in the United States (2) , resulting in more than 13,000 deaths, usually from metastatic disease.
Clear cell RCC (ccRCC), the most common type of RCC, is characterized by a dysregulation of hypoxia-inducible transcription factors resulting in the activation of several genes that regulate angiogenesis, such as vascular endothelial growth factor (VEGF) (3) .
Detailed investigation of these genetic pathways has identified multiple targets for therapeutic intervention; in the last decade, agents targeting the VEGF ligand and its receptors (VEGFR-1, -2, and -3) have become the standard of care for patients with advanced disease (3).
Sunitinib and pazopanib, as compared with interferon or placebo, respectively, have significantly improved progression-free survival (PFS) benefit in patients with advanced disease, and are widely established as first-line therapies in this setting (4, 5) . Recently, a large phase III, randomized trial (COMPARZ) compared the efficacy and safety of pazopanib versus sunitinib as first-line systemic treatment of patients with metastatic RCC (6) . This noninferiority study showed that pazopanib and sunitinib have similar efficacy, but different safety and quality-of-life profiles (7) . Although a number of potential biomarkers to predict response to targeted therapy have been investigated in RCC, none have entered clinical practice (8) .
The understanding of how tumor cells evade antitumor immune response has provided a rationale for new therapeutic strategies (9) . Immune checkpoint molecules such as programmed death-1 (PD-1) and the PD-1 ligand (PD-L1) are key regulators of T-cell-mediated response.
The interaction of PD-1 with its ligand (PD-L1 or B7-H1) negatively regulates T-cell activation (10). Therefore, by overcoming this adaptive mechanism with therapies that inhibit the 
MATERIAL AND METHODS

Patients and samples
We analyzed data from patients who were enrolled in the COMPARZ clinical trial, which was conducted in accordance with the Declaration of Helsinki. All patients provided written informed consent for participation in the clinical trial.
Between August 2008 and September 2011, this phase III study enrolled 1110 patients with metastatic ccRCC to randomly receive pazopanib (n=557) or sunitinib (n=553) at standard dosages. The primary endpoint was PFS, and the study was designed to evaluate the noninferiority of pazopanib versus sunitinib. Secondary end points included overall survival (OS), safety, and quality of life (6) . Formalin-fixed paraffin-embedded tumor blocks were available from 453 patients who provided consent for tissue analysis: 221 of 557 in the pazopanib arm and 232 of 553 in the sunitinib arm. Archival tumor tissue samples were collected at baseline from these 453 patients.
Immunohistochemistry
PD-L1 expression was retrospectively evaluated by immunohistochemistry using the monoclonal anti-PD-L1 mouse IgG1 antibody (clone 5H1) on the Leica automated immunohistochemistry platform (MEDTOX Laboratories, St. Paul, MN, USA) as previously described (22). All cases were also stained for CD8 using a commercially available monoclonal mouse antibody (4B11) on the Leica Bond platform using recommended antigen retrieval conditions and an alkaline phosphatase red detection system. Formalin-fixed paraffinembedded tonsil tissue was used as positive and negative control material for each staining run.
PD-L1 expression on tumor cell membrane was determined semi-quantitatively on a 0+ to 3+ scale: 0+, no appreciable staining above background; 1+, any degree of cytoplasmic or membranous staining above background, but less than 2+ or 3+; 2+, moderately to intensely Figure S1) .
Statistical analysis
The objectives of this study were to investigate the association between PD-L1 The association between PD-L1 HS and treatment outcomes (OS and PFS) was explored by the log-rank test across a sliding window of HS. The HS threshold was the minimum H-score with log-rank P<0.05. Multivariate analysis (Cox proportional hazards regression) was adjusted by individual adverse risk factors: Karnofsky Performance Score (KPS), lactate dehydrogenase (LDH), and number of metastatic sites. In Cox analysis of OS, data from pazopanib and sunitinib patients were combined. The association of rate of response (complete response or partial response vs stable disease or progressive disease) for patients with PD-L1 levels above and below the threshold was assessed using logistic regression.
All statistical analyses were post-hoc; computations were performed using SAS v.9.2 (SAS Institute Inc., Cary, North Carolina, USA), and a P value (two-sided) <0.05 was considered statistically significant. 
RESULTS
Patient and tumor characteristics
Patient and tumor characteristics are described in Table 1 . The KPS was 90 or 100 for 164 patients (74%) in the pazopanib arm and 169 patients (74%) in the sunitinib arm. In addition, the Memorial Sloan-Kettering Cancer Center (MSKCC) prognostic risk scores were considered favorable, intermediate, and poor for 64 (29%), 127 (57%), and 26 (12%) patients in the pazopanib arm, respectively, and 55 (24%), 142 (61%), and 24 (10%) patients in the sunitinib arm, respectively. The OS and PFS in the subset of patients who were included in the PD-L1 analysis (n=453) were comparable to the outcomes reported in the COMPARZ trial (Supplementary Table S1 ).
PD-L1 expression on tumor cells and immune cells
Formalin-fixed paraffin-embedded specimens were available from 453 of 1110 patients.
Overall, membranous PD-L1 expression in tumor cells was detected (HS>0) in 163 of 453 patients (36%); HS ranged from 0 to 290 ( Table 2) . A total of 85 patient samples (18.8%) showed a robust PD-L1 staining (2+ or 3+) ( Tables 3 and 4) . Interestingly, a robust PD-L1 signal was seen in fewer core biopsies than in tissue samples from surgical resections, although the numbers are too small to make definitive comparisons (Table 3) .
Overall, the dual staining with PD-L1 and CD68 identified 157 samples with moderate to numerous PD-L1-positive (PD-L1 + ) macrophages (Figure 1B) . In some of the cases, PD-L1 expression was determined to be exclusively on macrophages and no tumor expression was noted; these cases were excluded from the analysis. The correlation of PD-L1 expression on tumor cells and macrophages is summarized in Table 4 .
In addition, the inflammatory response as represented by the presence of peripheral
CD8
+ T cells in the invasive margin surrounding the tumor was graded as very strong in 36
Research. 1993 cases, strong in 31 cases, moderate in 161 cases, weak in 132 cases, and minimal in 38 cases.
In 88 cases, no invasive tumor/stromal margin was present in the tissue block analyzed.
Correlation of PD-L1 expression on tumor cells with treatment outcomes
An HS of >55 was found to be the threshold at which log-rank analysis demonstrated statistically significant association between HS and OS (P=0.0302, Figure 2) Figure S2) . Similarly, patients with HS>125 had significantly shorter PFS in both the pazopanib In addition, using an H-score threshold of 55, as we did for the PFS and OS endpoints, we did not find statistically significant differences in the rates of response for patients with PD-L1 levels above versus below the threshold (sunitinib P=0.6; pazopanib P=0.7).
Research. 
Combined effect of PD-L1 H-Score and CD8 level on OS
A combination of higher PD-L1 tumor expression and higher intratumor CD8 + cell counts correlated with shorter OS. In both arms, patients with both HS >55 and intratumoral CD8 + T-cell counts >300 had the shortest OS (11.9 months for sunitinib and 9.6 months for pazopanib).
Research.
on CCR-14-1993 showed that increased baseline PD-L1 expression, or increased PD-L1 expression plus intratumor CD8 + T-cell counts >300 at baseline, was associated with shorter OS in patients treated with sunitinib or pazopanib, suggesting that these patients may be ideal candidates for a therapeutic strategy that targets the PD-1/PD-L1 axis. PD-L1 immunohistochemistry protocols are used to assess PD-L1 in other studies; direct comparisons of our results with those of other investigations should be done with caution. We evaluated baseline PD-L1 expression, but the question of how different VEGF-targeted therapies may influence the expression of this biomarker in post-treatment biopsies still needs to be investigated. Finally, although we evaluated patients who were part of a clinical trial, we found that information was missing which could classify patients according to prognostic risk score groups. Therefore, in the multivariate analysis we include only known (ie, data not missing) single variables that impact the prognosis of RCC. The strengths of our study include the large number of patients who were part of a well-conducted clinical trial and the adjustment of the analysis for the prognostic risk factors previously associated with worse prognosis.
In conclusion, our study shows that PD-L1 expression is associated with treatment 
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